RxDoctor Payments Data

Yara Letitia Cameron, MD

Interventional Cardiology · Grand Forks, NDNPI 1245518802

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Boston Scientific at 40.9% of the total.

$7,889in general payments, 2019–2025

Across 45 payments — averaging $175.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$3K
  • Philips North America LLC$1K
  • Medtronic$100
  • Cardiovascular Systems Inc.$70
  • Actelion Pharmaceuticals US, Inc.$67
  • plus $275 from 11 others

What the payments were for

  • Consulting fees$2,00025%
  • Travel & lodging$4,30755%
  • Food & beverage$1,58220%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,516
Medicare patients
409
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$40,508
Repatha SureclickEvolocumab13$12,366
Bumetanide46$1,515
Ranolazine ErRanolazine13$1,300
Metoprolol Succinate93$898
Atorvastatin Calcium101$795
ClopidogrelClopidogrel Bisulfate73$698
Isosorbide Mononitrate ErIsosorbide Mononitrate52$591
Metolazone21$503
Amlodipine Besylate70$413
Losartan Potassium23$312
Lisinopril44$284
Furosemide58$259
Rosuvastatin Calcium25$251
Carvedilol24$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$40,50834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Grand Forks

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →